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background
Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, is 
causing a progressive disability that impacts patients’ quality of life and societal costs [1]. MS 
takes several forms, with new symptoms either occurring in isolated attacks (relapsing form) 
or building up over time (progressive form) [2]. Between attacks, symptoms may disappear 
completely; however, permanent neurological problems often remain, especially as the disease 
advances [2]. In 85% of patients with MS the onset form is relapsing-remitting MS (RRMS) 
[3]. While MS is currently considered incurable, treatment has advanced significantly over the 
past several decades. Disease modifying therapies (DMTs) can reduce the frequency of clinical 
relapses and delay disability progression [4]. As is the case in many different therapeutic areas, 
clinical progress in treating the disease has accompanied a rise in costs to purchase biologic 
products. In this light, economic evaluations are key elements for healthcare decision-making.
In 2016 we published in this journal a cost-effectiveness analysis that compared subcuta-
neous peginterferon beta-1a 125 μg every 2 weeks (Plegridy®) to the other injectable DMTs 
used in first-line therapy of RRMS from both the perspective of the Italian National Health-
care Service (NHS) and of the Italian Society [5]. The comparators considered in the analysis 
were: interferon (IFN) beta-1a 30 μg (Avonex®), IFN beta-1a 22 μg (Rebif® 22), IFN beta-1a 
44 μg (Rebif® 44), glatiramer acetate (GA, Copaxone®) 20 mg, IFN beta-1b 250 μg (Betafer-
on® and Extavia®). The 2016 analysis showed that peginterferon beta-1a was an alternative 
dominant or cost-effective vs IFNs and GA for the treatment of RRMS in Italy from the NHS 
and societal perspectives. While the design of the model and the choice of clinical parameters 
remains well aligned with the most recent cost-effectiveness studies published in the literature 
[6], some economic inputs of that analysis appear now outdated. The objective of the current 
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update of the cost-effectiveness analysis 
of peginterferon beta-1a in italy
The 2016 analysis [5] was conducted using a Markov model (Figure 1), reviewed and 
accepted by – among other agencies – the National Institute for Health and Care Excellence 
(NICE) in the UK [7]. The model simulates mortality, disease progression between EDSS lev-
els, relapse frequency and transition to secondary progressive multiple sclerosis (SPMS), esti-
mating the survival (life years; LYs), the survival adjusted for quality of life (quality-adjusted 
life years; QALYs), the overall costs, and the incremental cost per QALY gained (incremental 
cost effectiveness ratio; ICER). Twenty-one health states are included in the model: 10 states 
in the RRMS form; 10 states in the SPMS form; 1 state for death.
The simulation starts with a hypothetical cohort distributed among the different EDSS 
levels of RRMS, according to the initial distribution and demographic characteristics of the 
patients in the ADVANCE study, which compared the safety and efficacy of peginterferon 
beta-1a 125 μg every 2 weeks with placebo [8,9]. At each (annual) simulation cycle the 
patients can progress/regress between the EDSS levels or remain in the same EDSS level, 
progress to the SPMS form, have a relapse according to the specific probability in each 
health state, or die. Patients cannot return from SPMS to RRMS, nor regress to lower EDSS 
levels in the SPMS form (such transitions are possible in RRMS). The treatments included 
in the model can exert their effect by either slowing down the disability progression (com-
pared to the natural history of the disease) or by reducing the relapse incidence in the RRMS 
form. Treatment cannot affect the progression from RRMS to SPMS, the transition between 
EDSS levels in the SPMS form, or mortality. It is assumed that patients stop disease modi-
fying therapy when reaching an EDSS level ≥ 7 in the RRMS form, or on transition to the 
SPMS form.
Efficacy data were derived from a published network meta-analysis [10]. Each treatment 
is associated with specific adverse events that occur at frequencies reported in clinical stud-
ies. Health state utilities were derived from a cross-sectional study of the burden of illness of 
patients with MS in Italy [11]. Unit costs were based on current Italian prices and tariffs, and 
the published literature. Costs and utilities were discounted at 3.5% [12]. The model considers 
a time horizon of 50 years. Full details have been published previously in 2016 [5].
While the design of the model and the choice of clinical parameters remains well aligned 
with the most recent cost-effectiveness studies published in the literature [6], some economic 
Figure 1. CEA model structure. Modified from [5]
EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; State 
N = current EDSS state
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inputs of that analysis now appear outdated. Therefore, in the current analysis we reviewed all 
cost input data, with specific focus on the cost of drug purchase and the cost of relapse (Table 
I). The costs were updated to July 2018, by inflating them with consumer price index [13]. 
While ex-factory prices of most injectable DMTs were unchanged since 2016, we found a 
new Official Gazette for IFN beta-1a 22 µg and 44 µg [14]. Additionally, the source for direct 
medical and societal costs to manage a relapse, originally derived from Kobelt et al. [11], was 
changed to a more recent publication, namely the study from Battaglia et al. [15]. Further-
more, management costs for adverse events and routine costs by EDSS scores (Table I), based 
on Karampampa et al. [16], were revised based on current prices of generic products [17] and 
inflated to July 2018 [13]. Finally, the mortality tables of the general Italian population were 
aligned with the most recent evidence [18].
results of the updated analysis
Peginterferon beta-1a was more effective than all first-line injectable DMTs included in 
the analysis, both in terms of survival (LYs, discounted) and of survival adjusted for quality of 
Costs for the NhS (€/year) Costs for the Society (€/year)
RRMS SPMS RRMS SPMS
Routine management costs by EdSS score
0 207 5,467 1,378 9,668
1-1.5 207 5,467 1,378 9,668
2-2.5 207 5,467 1,378 9,668
3-3.5 652 19,377 12,802 51,743
4-4.5 652 19,377 12,802 51,743
5-5.5 652 19,377 12,802 51,743
6-6.5 652 19,377 12,802 51,743
7-7.5 5,854 9,834 34,992 76,443
8-8.5 5,854 9,834 34,992 76,443
9-9.5 5,854 9,834 34,992 76,443
Management cost of relapse 1,574 2,681
Table I. Revised routine management costs and relapse costs. Elaborated from [15,16]
RRMS 0-6,5: only costs for co-medications. Not included the costs for DMTs and other disease management costs (e.g., monitoring, etc.) considered in 
other calculation sections of the model















LYs 20.09 19.86 19.88 19.96 19.83 19.83 19.83
QALYs 9.09 8.11 8.21 8.57 8.08 8.08 8.17
Incremental QALYs 0.98 0.88 0.52 1.02 1.02 0.92
Cost (€)
Drugs + Monitoring 113,357 92,762 84,526 110,807 92,359 86,163 83,026
Relapses 5,896 6,261 6,091 5,884 5,910 5,910 5,706
Adverse events 102 154 107 151 110 110 94
Routine management 115,191 124,595 124,073 120,661 125,763 125,763 125,916
Total costs 234,548 223,770 214,798 237,502 224,143 217,947 214,742
Incremental costs 10,778 19,750 -2,955 10,404 16,601 19,805
ICER (€/QALY) 10,962 22,449 dominant 10,226 16,317 21,451
Table II. CEA of peginterferon beta-1a vs first-line injectable DMTs in Italy from the NHS perspective
1 Betaferon
2 Extavia
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life (QALYs, discounted) (Table II). Incremental QALYs gained ranged from 0.52 (peginter-
feron beta 1-a vs IFN beta-1a 44 μg) to 1.02 (peginterferon beta 1-a vs IFN beta-1b 250 μg).
The analysis from the perspective of the Italian NHS showed that the (discounted) total 
direct medical cost of a patient treated with peginterferon beta-1a was slightly higher than that 
of other DMTs, except for IFN beta-1a 44 μg (Table II). In the first cases, the higher drug cost 
was only partially offset by possible reductions in other cost categories.
Peginterferon beta-1a was dominant vs IFN beta-1a 44 μg because it was more effective 
and with lower costs and cost-effective versus the other first line injectable DMTs showing 
the following ICERs: € 10,962/QALY for IFN beta-1a 30 μg, € 22,449/QALY for IFN beta-1a 
22 μg, € 10,226/QALY for IFN beta-1b 250 μg (Betaferon®), € 16,317/QALY for IFN beta-
1b 250 μg (Extavia®), and € 21,451/QALY for GA 20 mg. In all cases, the ICER was below 
the commonly considered willingness-to-pay threshold for acceptability (€ 30,000-50,000/
QALY) (Table II).
When the analysis was performed in the perspective of the Italian Society, the total cost 
of a patient treated with peginterferon beta-1a was lower than those of all the comparators 
included in the analysis (Table III).
Peginterferon beta-1a was dominant vs all injectable first-line DMTs included in the anal-
ysis (IFN beta-1a, IFNβ-1b, GA); that is, it is more effective, in terms both of survival (LYs) 
and of survival adjusted for quality of life (QALYs), and with a lower total societal cost (Table 
III).
Sensitivity analyses (deterministic and probabilistic) confirmed that, from both NHS and 
societal perspectives, the base case results are robust to variations in input parameters, in line 
with the 2016 analysis [5].
conclusion
The model that was used to perform the cost-effectiveness analysis of peginterferon beta-
1a published in 2016 was updated in economic data (all cost now determined at July 2018) 
and in reference statistical data (i.e., tables of mortality of the general Italian population). No 
changes were made to the structure and design of the model, or to the clinical parameters used 
as inputs. The results of the updated analysis confirm and strengthen those published in 2016, 
showing that peginterferon beta-1a is a valid alternative in the treatment of RRMS as com-
pared to other available injectable first-line DMTs included in the model from the perspective 
of both the Italian NHS and the Italian society.
Funding















LYs 20.09 19.86 19.88 19.96 19.83 19.83 19.83
QALYs 9.09 8.11 8.21 8.57 8.08 8.08 8.17




113,357 92,762 84,526 110,807 92,359 86,163 83,026
Relapses 10,041 10,662 10,373 10,020 10,065 10,065 9,718
Adverse events 102 154 107 151 110 110 94
Routine 
management
664,715 735,002 730,957 704,933 744,146 744,146 745,346
Total costs 788,216 838,579 825,964 825,911 846,681 840,485 838,183
Incremental costs -50,363 -37,748 -37,695 -58,465 -52,269 -49,967
ICER (€/QALY) dominant dominant dominant dominant dominant dominant
Table III. CEA of peginterferon beta-1a vs first-line injectable DMTs in Italy from the societal perspective
1 Betaferon
2 Extavia
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